Skip to main content

Table 4 Positron emission tomography patterns in the reported studies pertaining to COVID-19 vaccination

From: Comparison of post-COVID-19 vaccination hypermetabolic lymphadenopathy on 18F-fluorodeoxyglucose PET/CT between virus-vector vaccine and mRNA vaccine

Country

Case

Vaccine

HLN(%)

HLN1(%)a

HLN2(%)a

HLN

SUVb

HLN

SUV1ab

HLN

SUV2ab

DL (%)

DL1 (%)a

DL2 (%)a

DL

SUVb

DL

SUV1ab

DL

SUV2ab

Israel [1]

650

BNT

26

15

43

 

3.7

4.5

      

Israel [2]

951

BNT

46

36

54

         

Israel [3]

205

BNT

29

   

2.9

       

Israel [4]

137

BNT

31

           

Switzerland [5]

140

BNT/M

54

  

5.1

4.1

5.4

      

Korea [6]

31

AZ

90

  

3.9

  

73

  

2.8

  

USA [7]

68

BNT/M

13

5

26

         

Israel [8]

377

mRNA

45

  

2.7

  

26

  

2.0

  

USA [9]

231

mRNA

47

        

1.8

  

Israel/UK [10]

274

NA

66

55

69

0.6–17.8c

  

12

     

Italy [11]

437

BNT/M/AZ

27

34

66

4.1

        

Israel [12]

179

BNT

48

  

2.4

        

UK [13]

204

BNT/AZ

36

  

1.9

        

France [14]

260

mRNA

35

  

3.7

        

Canada [15]

202

mRNA

62

  

2.5

        

Japan [16]

237

BNT

43

41

51

 

2.9

1.8

22

19

34

 

1.8

2.2

  1. HLN, hypermetabolic lymphadenopathy; DL, deltoid muscle uptake; BNT, Pfizer-BioNTech; M, Moderna; AZ, Oxford-AstraZeneca
  2. a HLN1, HLN incidence after the first dose; HLN2, HLN incidence after the second dose; DL1, DL incidence after the first dose; DL2, DL incidence after the second dose
  3. b SUV represented for maximal standard uptake value
  4. c Range
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us